116574-71-1

Basic information

• Product Name: N-Boc-piperidine-3-methanol
• Synonyms: (+/-)-BOC-3-PIPERIDINE METHANOL;N-(TERT-BUTOXYCARBONYL)-3-PIPERIDINEMETHANOL;N-BOC-(3S)-PIP(3-CH2OH);N-BOC-3-HYDROXYMETHYLPIPERIDINE;(+/-)-N-BOC-3-PIPERIDINE METHANOL;N-BOC-3-PIPERIDINYL-METHANOL;N-Boc-piperidine-3-methanol;TERT-BUTYL 3-(HYDROXYMETHYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE
• CAS NO: 116574-71-1
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• EINECS: 1308068-626-2
• Product Categories: pharmacetical;Piperidine;Heterocyclic Compounds;Building Blocks;C11;Chemical Synthesis;Heterocyclic Building Blocks;Piperidines
• Mol File: 116574-71-1.mol
• Article Data: 63

Chemical Properties

• Melting Point: 77-81°C
• Boiling Point: 308 ºC at 760 mmHg
• Flash Point: 140.1 ºC
• Appearance: Off-white solid
• Density: 1.059 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Soluble in methanol and dimethylformamide(DMF).
• PKA: 14.93±0.10(Predicted)
• CAS DataBase Reference: N-Boc-piperidine-3-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-piperidine-3-methanol(116574-71-1)
• EPA Substance Registry System: N-Boc-piperidine-3-methanol(116574-71-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 116574-71-1(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Uses

Different sources of media describe the Uses of 116574-71-1 differently. You can refer to the following data:
1. (+/-)-1-Boc-3-(hydroxymethyl)piperidine is used as a reactant for synthesis of Pim-1 inhibitors, Vasopressin1b receptor antagonists, CXCR4 antagonists as anti-HIV agents, Amide CCR5 antagonist, PSSRI-based inhibitors of S. aureus multidrug efflux pumps and Human GnRH receptor antagonists.
2. Reactant for synthesis of:Pim-1 inhibitorsVasopressin1b receptor antagonistsCXCR4 antagonists as anti-HIV agentsAmide CCR5 antagonistPSSRI-based inhibitors of S. aureus multidrug efflux pumpsHuman GnRH receptor antagonists

InChI:InChI=1/C11H21NO3/c1-11(2,3)15-10(14)12-6-4-5-9(7-12)8-13/h9,13H,4-8H2,1-3H3

Upstream product

• 4606-65-9 3-(hydroxymethy)piperidine 
• 850761-36-3 tert-butyl 3-iodo-1-piperidinecarboxylate 
• 50-00-0 formaldehyd 
• 108-05-4 vinyl acetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 498-95-3 (R)-nipecotic acid 
• 194726-46-0 (3R)-3-formylpiperidine-1-carboxylic acid tert-butyl ester 
• 445398-78-7 N-benzyl-hepta-4(E),6-dien-1-amine 
• 651321-53-8 Benzyl-[(E)-hepta-4,6-dien-(E)-ylidene]-amine 
• 79280-39-0 (4E)-hepta-4,6-dienal 
• 33741-15-0 methyl (4E)-hepta-4,6-dienoate 
• 140645-20-1 t-butyl (R,S)-3-<(butyryloxy)methyl>-1-piperidine-carboxylate 
• 108-30-5 succinic acid anhydride 
• 109-02-4 4-methyl-morpholine 

Downstream Products

• 116574-71-1 tert-butyl (3R)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 253177-03-6 3-iodomethylpiperidine-1-carboxylic acid tert-butyl ester 
• 118156-93-7 3-formylpiperidine-1-carboxylic acid tert-butyl ester 
• 140695-84-7 tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 144448-01-1 (S)-N-tert-butoxycarbonylpiperidin-3-ylmethyl acetate 
• 1140039-87-7 3-{4-Methyl-2-[3-(5-methyl-pyrazin-2-yl)-ureido]-phenoxymethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 876148-11-7 1-(tert-butoxycarbonyl)-3-[(4'-chlorobiphenyl-4-yl)oxymethyl]piperidine 
• 1002359-91-2 tert-butyl (3R)-3-(bromomethyl)piperidine-1-carbamate 
• 1246289-49-5 C₁₈H₂₀Cl₂N₂O 
• 876147-57-8 1-(tert-butoxycarbonyl)-3-[[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxymethyl]piperidine 
• 116574-72-2 3-(methoxymethyl)piperidine 
• 194726-46-0 (3R)-3-formylpiperidine-1-carboxylic acid tert-butyl ester 
• 191092-05-4 1-t-butoxycarbonyl-3-(p-toluenesulfonyloxymethyl)piperidine 
• 140645-87-0 (S)-<<(benzyloxycarbonyl)amino>methyl>piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Synthesis of substituted 1H-imidazol-1-ylmethylpiperidines. Facile separation of 1,4- and 1,5-disubstituted imidazoles

The synthesis of several 1H-imidazol-1-ylmethylpiperidines is described. A method for the regioselective isolation of 1,4-disubstituted imidazoles utilizing the selective quaternization of the 1,5-disubstituted regioisomer was developed.

Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants

A novel class of HIV-1 protease inhibitors with flexible piperidine as the P2 ligand was designed with the aim of improving extensive interactions with the active subsites. Many inhibitors exhibited good to excellent inhibitory effect on enzymatic activity and viral infectivity. In particular, inhibitor 3a with (R)-piperidine-3-carboxamide as the P2 ligand and 4-methoxybenzenesulfonamide as the P2’ ligand showed an enzyme Ki value of 29 pM and antiviral IC50 value of 0.13 nM, more than six-fold enhancement of activity compared to DRV. Furthermore, there was no significant change in potency against DRV-resistant mutations and HIV-1NL4?3 variant for 3a. Besides, inhibitor 3a exhibited potent antiviral activity against subtype C variants with low nanomole EC50 values. In addition, the molecular modeling revealed important hydrogen bonds and other favorable van der Waals interactions with the backbone atoms of the protease and provided insight for designing and optimizing more potent HIV-1 protease inhibitors.

NOVEL HISTONE METHYLTRANSFERASE INHIBITORS

The present invention relates to novel compounds of formula (I) as defined herein. The compounds are inhibitors of histone methyltransferases of the seven-beta-strand family, in particular of KMT9.

SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY

In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.